Paris, February 5th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announced today the completion of its phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized monoclonal antibody fragment (Fab) […]
Press Releases
February 5, 2018
ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS
January 20, 2018
Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital
Paris, January 4th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders Anaxago, […]
January 20, 2018
Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer
Paris, December 20th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the appointment of Dr Yannick Plétan as Chief Medical Officer. He will report to Gilles Avenard, CEO of Acticor Biotech and be responsible for […]
October 18, 2017
Acticor Biotech first-in-human clinical trial in healthy volunteers
Paris, October 17th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and myocardial infarction, today announced the agreement of Dutch Authorities for the initiation of a phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized fragment of […]
May 19, 2017
Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum
Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum Phase 1 to start in October 2017 Paris, May 18th, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, announced today that it has received its second payment from Mediolanum, triggered by […]
February 23, 2017
Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I
The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. Paris, February 23rd, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. The first-in-human study with ACT017 […]